Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4054)
All Articles published online
|
Publishing Process of This Article
|
Sep 6, 2021 (publication date) through Dec 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ. Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report. World J Clin Cases 2021; 9(25): 7498-7503 [PMID: 34616818 DOI: 10.12998/wjcc.v9.i25.7498] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i25/7498.htm |
| Number | Citing Articles |
| 1 |
Chang’e Jin, Zhengqiang He, Min Guo, Shengguo Liu, Yan Wang, Jinfan Qiu, Chenhui Li, Di Wu. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Anti-Cancer Drugs 2022; 33(7): 696 doi: 10.1097/CAD.0000000000001303
|
| 2 |
Alessandro Inno, Vincenzo Picece, Giuseppe Bogina, Giulio Settanni, Valeria Viassolo, Matteo Salgarello, Stefania Gori. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report. Clinical Lung Cancer 2024; 25(2): 175 doi: 10.1016/j.cllc.2023.10.012
|
| 3 |
Xin-mei Li, Yuan-dong Zheng, Yi-fan Zhang, Xia-juan Huan, Chen Yang, Meng-ling Liu, Xiao-kun Shen, Chun-hao Yang, Xing-xing Diao. Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats. Cancer Chemotherapy and Pharmacology 2022; 90(6): 499 doi: 10.1007/s00280-022-04485-5
|
| 4 |
Jonathan Soon Jian Hao, Chan Sock Hoai, Daniel Tan Shao Weng, Joanne Ngeow, Jianbang Chiang. Case report: olaparib use in metastatic lung adenocarcinoma withBRCA2pathogenic variant. Molecular Case Studies 2022; 8(7): a006223 doi: 10.1101/mcs.a006223
|
| 5 |
Zhujun Chen, Kang Wang, Lintao Zhao, Liang Gong. BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1190100
|
| 6 |
|
| 7 |
Auro del Giglio, Beatriz da Costa Aguiar Alves, André Márcio Murad, Fernando Luiz Affonso Fonseca. Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report. Journal of Medical Case Reports 2023; 17(1) doi: 10.1186/s13256-023-04139-x
|
| 8 |
Huimin Zhang, Xiaofeng Cong, Jiaxin Yin, Chen Chen, Ziling Liu. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1387388
|